Sunitinib

Sunitinib has been studied in 9 papers since 2016: 1 trial and 3 observational studies in people, 3 in animals, 1 in cells; 5 in the past year. It is an approved medicine. The newest story, Oct 6, 2026: “Sunitinib selectively killed senescent cells in the lab”.

InterventionApproved 2006

9 papers study it3 more mention it8 findingsUpdated

PubChemChEBIMeSH

1 new paper in 30 daysSee all 12 papers on sunitinib

At a glance

One study shows that sunitinib reduces senescent-cell abundance and SASP expression in mouse lungs with bleomycin-induced fibrosis and induces apoptosis in senescent human HDFs.

8 findings in 5 papers from 2016 to 2026, 1 of them since October 2026

The findings reach mice, none yet in people. 3 independent labs in 2 countries; 243 trials, none about aging, 88 with no results posted.

None of its findings points the other way.

Cells and mice: a single group. Worms or flies and humans: nothing yet.
  • 3 independent labs in 2 countries
  • 243 trials, none about aging, 88 with no results posted
  • Funders: Korea Ministry of Education and 8 more
  • 1 of 243 trials sponsored by its developers
  • Human trial1
  • Humans3
  • Animals3
  • Cells1
  • In silico1

What did studies of sunitinib find?

7

Studies of sunitinib measured 7 outcomes, among them SASP expression, senescent cell count and apoptosis.

SASP expression

downin mice1

1 study
  1. Sunitinib decreases SASP expression in mice (bleomycin-induced lung fibrosis).

    Animalsbleomycin-induced lung fibrosislung

    Sunitinib selectively killed senescent cells in the lab

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

More on SASP expression

Senescent cell count

downin mice1

1 study
  1. Sunitinib decreases senescent cell count in mice (bleomycin-induced lung fibrosis).

    Animalsbleomycin-induced lung fibrosislung

    Sunitinib selectively killed senescent cells in the lab

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

More on Senescent cell count

Apoptosis

upin human cells1

1 study
  1. Sunitinib induces apoptosis in human cells (senescent cells).

    Cellssenescent cellshuman dermal fibroblast

    Sunitinib selectively killed senescent cells in the lab

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

More on Apoptosis

Cognitive function

upin mice1

1 study
  1. Sunitinib improves cognitive function in mice (APP/PS1 mice).

    AnimalsAPP/PS1 mice

Tumor-free survival

upin mice1

1 study
  1. Sunitinib increases tumor-free survival in mice (obesity-associated postmenopausal breast cancer models).

    Animalsobesity-associated postmenopausal breast cancer models

Acquisition of the vascular phenotype

downin mice1

1 study
  1. Sunitinib decreases acquisition of the vascular phenotype in mice (obesity-associated postmenopausal breast cancer models).

    Animalsobesity-associated postmenopausal breast cancer modelsbreast tumor

Malignant peripheral nerve sheath tumor

downin zebrafish1

1 study
  1. Sunitinib decreases malignant peripheral nerve sheath tumor in transgenic fish overexpressing wild-type PDGFRA.

    Animalsin transgenic fish overexpressing wild-type PDGFRA

More on Malignant peripheral nerve sheath tumor

What is sunitinib linked with?

1

Studies link sunitinib with senescence score.

Senescence score

upin silico1

1 study
  1. Senescence score predicts sunitinib in silico (high-score subgroup vs low-score subgroup).

    In silicohigh-score subgroup vs low-score subgroup

More on Senescence score

Has sunitinib been tested in people?

0 of 243 about aging

Yes: 1 trial and 3 observational studies in people have been published, and 242 trials are registered.

Approved

  • EMA Sutent

    Jul 19, 2006Gastrointestinal Stromal Tumors, Carcinoma, Renal Cell, Neuroendocrine Tumors, Metastatic Renal Cell Carcinoma

  • EMA Sunitinib Accord

    Feb 11, 2021Gastrointestinal Stromal Tumors, Carcinoma, Renal Cell, Neuroendocrine Tumors, Metastatic Renal Cell Carcinoma

Repurposing

40 of 78

In trials

  • Refractory solid tumour

    Phase 4Completed1 trial

  • Prostatic neoplasm

    Phase 3Terminated9 trials

  • Leukemia myeloid acute

    Phase 2Terminated4 trials

  • Clear cell metastatic renal cell carcinoma

    Phase 2Completed3 trials

  • Fallopian tube neoplasm

    Phase 2Results posted3 trials

  • Follicular Adenocarcinoma

    Phase 2Results posted3 trials

All 30

Stopped

  • NCT00676650TerminatedProstatic neoplasm

    Study A6181120 was prematurely discontinued due to futility on 27 September 2010. No new or unexpected safety issues were identified.

  • NCT00910039TerminatedNeoplasm metastasis

    Slow Accrual

  • NCT01784978TerminatedNeoplasm metastasis

    Lack of recruitment

  • NCT01042795TerminatedBladder tumors

    Study closed due to poor accrual

  • NCT01216657TerminatedMelanoma

    slow recruitment

  • NCT00982657TerminatedSolid tumor

    Refer to statement in Summary Section/Detailed Description

All 15

Who is developing sunitinib?

2 companies: Genentech and Cogent Biosciences.

Companies
  • GenentechPhase 2non-small cell lung cancer
  • Cogent BiosciencesPhase 1/2gastrointestinal stromal tumor

Trial sponsors

How this record changed

  1. Summary written from the findings.

Latest

Dec 2025: 1Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 1May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 1Sep 2026: 0Oct 2026: 2Nov 2026: 16 papers in 12 months
Biomedicine & Pharmacotherapy

Sunitinib selectively killed senescent cells in the lab

A drug screen in human connective-tissue cells linked the selective killing effect to a protein that receives growth signals.A drug screen in human connective-tissue cells linked the selective killing effect to a protein that receives growth signals.

Experiments in human cellsInterventions
Neurotherapeutics

Enzyme-blocking drugs linked to lower Parkinson disease risk

Among 11 drugs examined, sorafenib prescription fills were linked to a relative risk of 0.43 for Parkinson disease compared with no fills for that drug.Among 11 drugs examined, sorafenib prescription fills were linked to a relative risk of 0.43 for Parkinson disease compared with no fills for that drug.

Case-control studyParkinson's disease

See all 12 papers on sunitinib